S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$8.37
$8.37
50-Day Range
$8.33
$8.40
52-Week Range
$2.66
$8.55
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
150.9% Upside
$21.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.70) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

531st out of 981 stocks

Pharmaceutical Preparations Industry

241st out of 461 stocks


CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

"How war impacts the stock market"
Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks"
He called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything.
See More Headlines


CNCE Company Calendar

Last Earnings
11/09/2021
Today
6/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+150.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52

Key Executives

  • Roger D. TungRoger D. Tung
    President, Chief Executive Officer & Director
  • Nancy StuartNancy Stuart
    Chief Operating Officer
  • Marc A. BeckerMarc A. Becker
    Chief Financial & Accounting Officer
  • Mitch K. Goldenberg
    VP-Information Technology & Infrastructure
  • Virginia Braman
    Vice President-Clinical Development













CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares.
View CNCE analyst ratings
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 12 month price targets for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 150.9% from the stock's current price.
View analysts price targets for CNCE
or view top-rated stocks among Wall Street analysts.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analyst estimates of $0.25 million. During the same quarter in the previous year, the firm posted ($0.60) EPS.

What ETF holds Concert Pharmaceuticals' stock ?

AltShares Event-Driven ET holds 2,000 shares of CNCE stock, representing 0.54% of its portfolio.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (0.00%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt and Roger D Tung.
View institutional ownership trends
.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $8.37.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $401.26 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -